MULTIPLE MYELOMA

This study looks at whether the PCV13 pneumonia vaccine is safe and helps prevent serious infections in people with multiple myeloma. About 100 participants will receive either one or two doses of the vaccine. Researchers will check how well the immune system responds and track s…

This study tests different COVID-19 booster vaccines in 960 immunocompromised people, including those with HIV, organ transplants, or blood cancers. The goal is to find which booster schedule gives the strongest and safest immune response. Results will help doctors protect these …

This study tests whether adding daratumumab to three standard drugs (carfilzomib, lenalidomide, and dexamethasone) is safe and effective for people newly diagnosed with multiple myeloma. About 75 participants will receive the four-drug combination. The main goal is to see how man…

This study tests a combination of two drugs (talquetamab and teclistamab) that help the immune system attack myeloma cells. It involves 228 adults with relapsed or refractory multiple myeloma, including those with tumors outside the bone marrow. The goal is to find the best dose,…

This early-stage trial tests a new drug called cevostamab, given alone or with other medicines, in about 126 people whose multiple myeloma has returned or not responded to prior treatments. The main goals are to find the safest dose and check for side effects. Researchers will al…

This study tests whether adding daratumumab to a standard three-drug regimen (carfilzomib, lenalidomide, dexamethasone) can better control multiple myeloma in newly diagnosed patients. About 310 participants will receive either the three-drug or four-drug combination. The main go…

This study tests whether adding lenalidomide to the standard chemotherapy (melphalan) before a stem cell transplant can improve outcomes for people with relapsed multiple myeloma. About 52 participants will receive the combination, followed by maintenance lenalidomide. The goal i…

This early-phase trial tests a new treatment for multiple myeloma, a cancer of the bone marrow. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that carry a protein called BCMA. Some participants also receive lenalidomide, a standard d…

This study tests whether adding the investigational drug isatuximab to a standard four-drug combination can improve treatment response in people newly diagnosed with multiple myeloma. About 52 adults aged 75 or younger who need treatment will receive the combination before a stem…

This study tests whether adding the drug belantamab mafodotin to a standard three-drug regimen can better control multiple myeloma, a type of blood cancer. About 70 adults will receive the combination to find the safest dose and see how many achieve a complete response. The goal …

This early-phase study tests a three-drug combination (iberdomide, elotuzumab, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find a safe dose and see if the combo can shrink tumors. About 37 adults will …

This study tests a combination of two drugs, belantamab mafodotin and feladilimab, in about 25 adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goals are to check safety and find the best dose. This is not a cure, …

This program provides access to REGN5458 for patients with multiple myeloma that has come back or stopped responding to other treatments. The goal is to control the cancer and improve outcomes. Participants receive the drug under compassionate use, meaning it is given outside of …

This study tests a three-drug combination (ixazomib, lenalidomide, and dexamethasone) given after a stem cell transplant to people with multiple myeloma. The goal is to see if this treatment can keep the cancer away longer. After four cycles, participants receive one of two maint…

This study tests whether a new combination of drugs (iberdomide, daratumumab, and dexamethasone) works better than the current standard treatment for people whose multiple myeloma has returned or stopped responding to earlier therapy. About 939 adults with 1–2 prior treatments ar…

This study looks at whether giving palifermin and leuprolide acetate can speed up immune recovery in people who have had a stem cell transplant for blood cancers like leukemia or lymphoma. The transplant uses donor stem cells to replace the patient's blood system. The goal is to …

This early-phase study tests a new drug, belantamab mafodotin, added to standard medications (bortezomib, lenalidomide, dexamethasone) for adults newly diagnosed with multiple myeloma. About 118 participants will receive different schedules of the new drug to find the safest and …

This study tests a new way to give the drug isatuximab—as a quick shot under the skin instead of a long IV drip—for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. About 74 participants aged 65 and older will receive the shot along wi…

This study tests an experimental drug called cevostamab in people with multiple myeloma that has returned or not responded to other treatments. About 90 participants who have already tried a type of BCMA-targeted therapy will receive the drug through an IV. The goal is to see if …

This study tests a combination of four drugs (elotuzumab, pomalidomide, bortezomib, and dexamethasone) in 52 adults with multiple myeloma that has returned or not responded to at least two prior treatments. The goal is to see how many patients achieve at least a partial response …

This early-phase study tests the safety of combining TTI-622 (a drug that helps the immune system attack cancer cells) with daratumumab (a standard myeloma treatment) in people whose multiple myeloma has returned or stopped responding to prior therapies. Researchers will find the…

This study tests a new drug called TNB-383B in people with multiple myeloma that has come back or not responded to at least three prior treatments. The drug is designed to help the immune system attack cancer cells. The main goals are to find the safest dose and see how well it c…

This early-stage study tests a new drug called teclistamab combined with other cancer treatments for people with multiple myeloma, a type of blood cancer. The main goal is to check safety and find the best doses. About 140 participants who have already tried other treatments will…

This study looks at whether multiple myeloma patients who have no signs of cancer after a stem cell transplant can safely stop their maintenance therapy. About 68 adults who have been on maintenance drugs for at least a year will be tested using advanced imaging and lab methods t…

This study tests whether adding daratumumab, a newer multiple myeloma drug, to standard therapy helps people with newly diagnosed myeloma live longer without their cancer getting worse. About 50 participants will receive the drug as part of a total treatment plan. The goal is to …

This early-stage study is testing a new drug called HPN217 (also known as MK-4002) in about 100 people whose multiple myeloma has returned or no longer responds to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body process…

This study is testing an experimental pill called CFT7455 in people with Non-Hodgkin's lymphoma or multiple myeloma whose cancer has returned or is no longer helped by standard treatments. The main goals are to check the drug's safety and find the best dose. About 224 adults will…

This study tests a combination of four drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) in 41 people with multiple myeloma that has spread to organs or tissues outside the bones, like the skin or liver. The goal is to see if this treatment can shrink or contro…

This study tests a three-drug combination (isatuximab, lenalidomide, and dexamethasone) in 30 adults with multiple myeloma who still have tiny amounts of cancer cells in their bone marrow after a stem cell transplant. The goal is to see if the treatment can make those leftover ce…

This study tests whether a combination of four chemotherapy drugs can improve outcomes for people with high-risk multiple myeloma. Participants receive carfilzomib, daratumumab, lenalidomide, and dexamethasone to kill cancer cells and stop them from growing. The goal is to see if…

This study tests a new drug called belantamab mafodotin against a standard combination therapy (pomalidomide plus dexamethasone) in 325 adults with multiple myeloma that has returned or stopped responding to prior treatments. Participants are randomly assigned to receive either t…

This study compares two treatments for newly diagnosed multiple myeloma in people up to age 65. One group gets a combination of three drugs (lenalidomide, bortezomib, and dexamethasone), while the other gets the same drugs plus high-dose therapy and a stem cell transplant. The go…

This early-stage study tests a new drug, sotatercept, combined with two standard treatments (lenalidomide or pomalidomide plus dexamethasone) in 33 adults with multiple myeloma that has returned or not responded to prior therapy. The main goal is to find the safest dose of sotate…

This early-stage study tests combinations of daratumumab (a targeted antibody) with two other drugs (talquetamab and teclistamab) in 290 adults with multiple myeloma, a type of blood cancer. The goal is to find the safest and most effective doses and to monitor side effects. Part…

This study tests a treatment plan that adjusts medications based on how well the cancer responds in adults aged 65 and older with newly diagnosed multiple myeloma. The main goal is to see how many patients achieve a significant reduction or disappearance of cancer signs. The appr…

This study tests a three-drug combination (isatuximab, pomalidomide, and dexamethasone) at lower-than-standard doses in people with multiple myeloma that has returned or not responded to treatment. The goal is to see if the lower doses are both safe and effective for patients who…

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The goal is to track long-term safety and side effects. About 165 adults are taking part, and they must continue to tolerate the drug well.

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have returned or not responded to prior treatments. The drug delivers radiation directly to cancer cells. A…

This study tests a new version of the chemotherapy drug melphalan, called Captisol Enabled Melphalan, in 46 adults with multiple myeloma or AL amyloidosis who are getting a stem cell transplant. The new formulation is designed to be more stable and possibly cause fewer side effec…

This study compares two drug combinations for people with multiple myeloma that has returned or stopped responding to treatment. One group gets belantamab mafodotin plus standard drugs, the other gets daratumumab plus standard drugs. The goal is to see which combo works better at…

This study tests a new treatment called JNJ-68284528, a CAR-T cell therapy, for people with multiple myeloma, a type of blood cancer. The goal is to see if it can make cancer undetectable in the bone marrow (called minimal residual disease negative). About 210 adults who have alr…

This study monitors the safety and effectiveness of the drug ELREXFIO (elranatamab) in 150 Korean adults with multiple myeloma who have already tried at least three other treatments. Researchers will track side effects and how well the drug controls the cancer in everyday medical…

This study tests a combination of four drugs (carfilzomib, lenalidomide, dexamethasone, and daratumumab) given before and after a stem cell transplant for people whose multiple myeloma has returned after prior treatment. The goal is to see if this intensive approach can lead to c…

This study tests whether adding a one-time CAR T-cell treatment (idecabtagene vicleucel) to standard lenalidomide maintenance therapy can better control multiple myeloma in adults who had a stem cell transplant but didn't get a full response. About 79 participants will receive ei…

This study compares two drug combinations (KRd and VRd) in 250 people newly diagnosed with multiple myeloma. The goal is to see which combination better delays cancer progression. Participants will receive one of the two treatments, and researchers will track how long they live w…

This phase 3 study tests whether adding daratumumab to lenalidomide after a stem cell transplant helps people with multiple myeloma live longer without the disease getting worse. About 1,100 participants receive either lenalidomide alone or lenalidomide plus daratumumab for up to…

This study tests a combination of drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) as a first treatment for multiple myeloma patients who are not eligible for a stem cell transplant. After initial treatment, patients receive maintenance therapy with daratumuma…

This early-stage study tests a new drug called CLN-619 in 30 adults with multiple myeloma that has returned or not responded to other treatments. The drug is an antibody designed to help the immune system attack cancer cells. The main goals are to check safety and see if the drug…

This study tests whether adding daratumumab to the standard maintenance drug lenalidomide can clear remaining cancer cells in people with multiple myeloma who still have traces of disease after a stem cell transplant. About 200 participants will receive either the combination or …

This study tests a new drug, belantamab mafodotin, combined with standard therapy (VRd) in 50 adults newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if the combination is safe and effective. Patients receive several cycles of …

This study tests a combination of four drugs (daratumumab, carfilzomib, lenalidomide, and dexamethasone) in 75 people newly diagnosed with multiple myeloma. The goal is to see how many achieve a very deep remission (stringent complete response) and have no detectable cancer cells…

This early-stage study tests a new drug (XmAb24306) combined with another drug (cevostamab) in about 90 people whose multiple myeloma has returned or stopped responding after at least three prior treatments. The main goal is to check safety and find the best dose. Researchers wil…

This study tests a combination of two treatments—cilta-cel (a cell therapy) and talquetamab (a targeted drug)—in people with high-risk multiple myeloma that has not responded well to prior therapies. The main goal is to check safety, and researchers will also measure how many pat…

This study tests whether a new drug combination (belantamab mafodotin plus bortezomib and dexamethasone) works better than a standard treatment for people with multiple myeloma that has come back or stopped responding to therapy. About 494 adults with this blood cancer will be ra…

This study tests whether adding iberdomide (taken as a pill) together with other drugs can clear tiny amounts of multiple myeloma that remain after a stem cell transplant. About 80 adults with newly diagnosed myeloma who still have detectable disease after transplant will receive…

This study tests whether adding the drug daratumumab to a standard three-drug combination (VRd) helps people with newly diagnosed multiple myeloma live longer without their cancer getting worse. About 709 patients aged 18 to 70 who are healthy enough for high-dose therapy will ta…

This study tests a combination of four drugs (daratumumab, carfilzomib, lenalidomide, and dexamethasone) in 39 adults newly diagnosed with multiple myeloma, a blood cancer that is not yet curable. The goal is to see how many patients achieve a complete or near-complete disappeara…

This study tests a combination of four drugs (daratumumab, clarithromycin, pomalidomide, and dexamethasone) in people with multiple myeloma whose cancer returned or stopped responding after previous treatment with daratumumab. The goal is to see if this combo can shrink tumors mo…

This study tests a combination of three drugs (bortezomib, lenalidomide, and dexamethasone) in 68 adults newly diagnosed with multiple myeloma, a blood cancer. The goal is to find the safest dose and see how well the drugs work together to shrink or control the cancer. Participan…

This study tests a combination of three drugs (ixazomib, pomalidomide, and dexamethasone) given twice a week to people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if this combination can control the cancer and how safe it is. Ab…

This study follows 200 adults with multiple myeloma that has come back or stopped responding to treatment. Researchers are tracking how well the drug teclistamab works and what side effects occur when used in everyday medical practice. The main goal is to see how many patients ac…

This study tests a combination of four drugs (isatuximab, pomalidomide, elotuzumab, and dexamethasone) in people with multiple myeloma that has come back or stopped responding to at least two prior treatments. The goal is to see how well the drug combo controls the cancer. About …

This phase 3 study tests a new drug combination (belantamab mafodotin plus bortezomib and dexamethasone) against a standard combination (daratumumab plus bortezomib and dexamethasone) in 72 Chinese participants whose multiple myeloma has returned or stopped responding to prior tr…

This early-phase study tests whether romosozumab, a drug that builds bone, is safe and effective for postmenopausal women who have both multiple myeloma and osteoporosis. The study involves 10 participants and measures changes in bone formation markers. It aims to find a new way …

This study tests whether adding the drug selinexor to standard treatments (carfilzomib, daratumumab, or pomalidomide) can help people with multiple myeloma whose cancer has worsened on their current therapy. About 96 adults will receive the combination until their disease progres…

This study tested a new treatment called BCMA CAR-T cell therapy for people with a high-risk type of multiple myeloma that still showed signs of disease after a stem cell transplant. The goal was to see if the therapy could safely eliminate remaining cancer cells. However, the st…

This early-stage study tests the safety and best dose of talquetamab when combined with other cancer drugs for people with multiple myeloma, a type of blood cancer. About 166 participants will receive different drug combinations to see how well they tolerate the treatment and wha…

This phase 2 study tests whether adding nivolumab after CAR-T cell therapy (ide-cel) can improve outcomes for people with relapsed/refractory multiple myeloma who did not achieve a complete response. The trial enrolled 1 adult participant with measurable disease and good performa…

This study follows about 100 people with multiple myeloma who have already received the experimental cell therapy P-BCMA-101. Researchers will track them for up to 15 years to check for delayed side effects and see how long the treatment's anti-cancer effects last. The goal is to…

This early-phase trial tests a new treatment called MCARH109 for people with multiple myeloma that has come back or not responded to at least three prior therapies. The treatment uses the patient's own immune cells, modified to recognize and attack a protein called GPRC5D on myel…

This study tests two targeted drugs, dabrafenib and trametinib, in 30 people with multiple myeloma that has returned or not responded to prior treatments. The goal is to see if these drugs can shrink the cancer. This is an early-phase trial focused on safety and effectiveness.

This study tests a combination of four drugs (belantamab mafodotin, nirogacestat, pomalidomide, and dexamethasone) in people with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to find the safest dose and see how well the comb…

This study tests whether a single infusion of cilta-cel (a CAR-T therapy that targets cancer cells) works better than standard maintenance drugs for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. About 743 participants will receive initial ch…

This study tests whether combining two drugs (lenalidomide and CC-486) with radiation therapy is safe and effective for people with plasmacytoma, a type of plasma cell tumor that can be linked to multiple myeloma. About 21 participants will receive the treatment to see if it lead…

This study tests a modified, less intense drug schedule for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The standard treatment requires two drug doses per week, which can be hard to tolerate. This study gives the drugs once a week to …

This study tests a new drug called CC-220, alone or with other medicines, in people with multiple myeloma, a type of blood cancer. The goal is to find the safest dose and see if the drug helps shrink tumors. About 466 adults with relapsed or newly diagnosed myeloma are taking par…

This study tests a combination of two drugs, belantamab mafodotin and isatuximab, in people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to find the safest and most effective dose and see how well the combination c…

This phase 3 study compares a new combination of two drugs (teclistamab and daratumumab) against two standard three-drug combinations for people with multiple myeloma that has come back or stopped responding to prior treatments. About 587 participants will be randomly assigned to…

This early-stage study tests a combination of three drugs—belantamab mafodotin, nirogacestat, and pomalidomide—in people whose multiple myeloma has returned or stopped responding to prior treatments. The main goal is to find the safest dose and see if the combination can slow or …

This early-phase study tests an experimental drug called etentamig (ABBV-383) in about 55 adults with multiple myeloma that has returned or stopped responding to prior therapies. The drug is given as a shot under the skin or through an IV. The main goals are to check safety, side…

This study tests whether adding daratumumab (given as a shot under the skin) to the standard drug lenalidomide helps frail older adults with newly diagnosed multiple myeloma live longer without their cancer getting worse. About 294 participants aged 65 and older who cannot have a…

This study tests two oral drugs, mirdametinib and sirolimus, in adults with relapsed or refractory multiple myeloma that has specific gene changes (KRAS or NRAS). The goal is to find a safe dose and see if the combination can shrink or control the cancer. Participants take the dr…

This study tests a new CAR-T cell therapy called anitocabtagene-autoleucel (CART-ddBCMA) in 136 adults with multiple myeloma that has relapsed or not responded to at least three prior treatments. The therapy targets a protein called BCMA on myeloma cells. The main goal is to see …

This study tested a new combination of drugs (carfilzomib, clarithromycin, lenalidomide, and dexamethasone) in 74 people with newly diagnosed multiple myeloma. The goal was to see how well the treatment worked and if it was safe. After the initial treatment, patients continued on…

This study compares two treatments for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. One group gets a combination of drugs (DVRd) followed by a new CAR-T cell therapy called ciltacabtagene autoleucel. The other group gets the same drugs…

This phase 3 study tests whether adding daratumumab to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) helps people with newly diagnosed multiple myeloma who are not planning a stem cell transplant. About 395 participants receive either the four-drug c…

This early-stage study tests an experimental pill called LOXO-338 in people with advanced blood cancers (like certain leukemias, lymphomas, and multiple myeloma) who have already tried standard treatments. The main goals are to find the safest dose and to see if the drug can shri…

This study looks at two different maintenance drugs for people with newly diagnosed multiple myeloma that has responded well to initial treatment. Participants will receive either the standard drug lenalidomide or daratumumab, and researchers will track which one leads to better …

This study is for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. It tests a combination of four drugs: belantamab mafodotin, nirogacestat, lenalidomide, and dexamethasone. The goal is to find a safe dose and see how well …

This study tests a new treatment called cilta-cel, which uses a patient's own immune cells to fight multiple myeloma, against two standard drug combinations. The trial involves 419 adults whose cancer has returned and no longer responds to the drug lenalidomide. The main goal is …

This study looks at whether using two drugs (an immunomodulatory drug plus a proteasome inhibitor) as maintenance therapy after a stem cell transplant works better than one drug alone for people with multiple myeloma. The goal is to see if the combination can turn cancer markers …

This early-stage study tests an experimental therapy called P-BCMA-ALLO1 for people with multiple myeloma that has come back or stopped responding to standard treatments. The therapy uses donor immune cells engineered to target and kill myeloma cells. The main goals are to check …

This study tested a combination of four drugs (carfilzomib, lenalidomide, vorinostat, and dexamethasone) in 17 people with multiple myeloma that had come back or stopped responding to treatment. The main goal was to find a safe dose and see if the combination could help control t…

This phase 3 study tests whether adding the drug isatuximab to a standard two-drug regimen (lenalidomide and dexamethasone) works better with or without a third drug (bortezomib) for older adults (65-79) newly diagnosed with multiple myeloma who are not eligible for a stem cell t…

This study tests a new drug called elranatamab in people with multiple myeloma, a type of blood cancer, whose cancer has not responded to at least three other treatments. The drug works by helping the body's immune cells attack the cancer cells. The main goal is to see how many p…

This study tests a new combination of drugs (Dara-SVD) against the usual treatment for people with a high-risk form of newly diagnosed multiple myeloma. The new combo adds a drug called selinexor, which is normally used only after the cancer returns. The goal is to see if using i…

This study tests whether adding T-cell redirecting drugs (teclistamab and talquetamab) to standard therapy can eliminate remaining cancer cells in people with newly diagnosed multiple myeloma. About 103 adults under 66 will receive one of two drug combinations based on their mini…

This study tests whether adding two extra drugs (carfilzomib and dexamethasone) to standard lenalidomide maintenance therapy after a stem-cell transplant can delay the return of multiple myeloma. About 180 adults who have already had a transplant and are in stable condition will …

This study tests a drug called belantamab mafodotin, alone or with other cancer drugs, in people with multiple myeloma that has come back or stopped responding to treatment. About 208 adults who have already tried at least three other treatments will take part. The goal is to see…

This phase 3 trial tests whether adding the drug isatuximab to standard treatment helps people with newly diagnosed multiple myeloma. About 662 participants will receive either standard therapy or standard therapy plus isatuximab. The goal is to see if the new combination leads t…

This study tests a new drug called elranatamab (given as a shot) against the standard drug lenalidomide (taken as a pill) in people with newly diagnosed multiple myeloma who have already had a stem cell transplant. The goal is to see if elranatamab can keep the cancer from coming…

This study tests a combination of four drugs (carfilzomib, lenalidomide, dexamethasone, and isatuximab) in 50 adults with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. The goal is to see how many patients achieve a complete response after four trea…

This study is for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. It tests a combination of two drugs—belantamab mafodotin and nirogacestat—to see if they are safe and can shrink or control the cancer. About 106 adults wil…

This study tests a new treatment plan for people newly diagnosed with multiple myeloma, a type of blood cancer. The goal is to see if adding a drug called bortezomib to a series of high-dose chemotherapy and stem cell transplants works better than previous treatments, especially …

This study looks at which initial treatment works best for older adults (65+) with multiple myeloma who cannot have a stem cell transplant. It compares standard drug combinations with or without the added drug daratumumab. The goal is to find the most effective approach while con…

This study tests a new three-drug combination (selinexor, pomalidomide, and dexamethasone) against another standard combination (elotuzumab, pomalidomide, and dexamethasone) in 117 adults with multiple myeloma that has come back or stopped responding to prior treatments. Particip…

This program provides pre-approval access to teclistamab for people with relapsed or refractory multiple myeloma who have no other treatment options left. Participants must have tried and failed all standard therapies, including proteasome inhibitors, IMiDs, and anti-CD38 antibod…

This early-phase study tests a new treatment for multiple myeloma that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are modified in the lab to recognize and attack myeloma cells. The main goal is to find the saf…

This study compared two treatment combinations for people newly diagnosed with multiple myeloma who cannot have high-dose therapy. One group received melphalan, prednisone, and thalidomide (MPT); the other received melphalan, prednisone, and lenalidomide (MPR). The goal was to se…

This study tests a drug called selinexor combined with other standard treatments for multiple myeloma, a type of blood cancer. It includes 300 adults with either newly diagnosed or relapsed/refractory disease. The goal is to find safe doses and see how well the combinations contr…

This early-phase trial tests a combination of four drugs (cyclophosphamide, pomalidomide, dexamethasone, and daratumumab) in people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to find the safest dose and see if the combination ca…

This study tests whether adding the drug BL-8040 to standard G-CSF helps collect more stem cells for transplant in people with multiple myeloma. About 180 participants were randomly assigned to receive either the combo or a placebo. The goal is to see if the combo leads to a succ…

This study tests whether a CAR-T cell therapy called cilta-cel is safe and effective for people with high-risk smoldering myeloma, an early form of multiple myeloma. About 20 participants will receive the treatment along with chemotherapy to prepare their immune system. The goal …

This study tests whether adding plinabulin to the standard drug pegfilgrastim can help white blood cell counts return to normal faster after a stem cell transplant in people with multiple myeloma. About 17 adults aged 18-75 are taking part. The goal is to reduce the time patients…

This study tests different sequences of advanced cell and antibody therapies (Cilta-cel, Tal-D, Tec-D) after initial chemotherapy in 43 people with newly diagnosed multiple myeloma. The goal is to see if these combinations can achieve deep, lasting remission with no detectable ca…

This early-stage study tests two new drug combinations for people with multiple myeloma that has come back or stopped responding to treatment. About 59 adults will receive elranatamab (a shot under the skin) plus either carfilzomib and dexamethasone or another drug called maplirp…

This study tests a treatment called ide-cel (a type of CAR T cell therapy) for people with multiple myeloma that has returned or not responded to treatment. Participants have already had a stem cell transplant. The goal is to see if these specially engineered immune cells can be …

This early-phase study tests whether the drug itacitinib can prevent cytokine release syndrome (a severe inflammatory reaction) and reduce the need for long-term immune-suppressing medications after a stem cell transplant. The trial involves 32 older adults (age 60+) with certain…

This study looks at how well the drug ixazomib works and what side effects it causes in adults with multiple myeloma who have already tried a different treatment. The goal is to see if switching to ixazomib can help control the disease longer. About 72 people are taking part in t…

This study looks at whether a single urine sample can accurately detect myeloma proteins compared to the standard 24-hour urine collection. Researchers will enroll 180 multiple myeloma patients starting a new treatment. If successful, this could make monitoring much easier for pa…

This study is testing whether a new radioactive tracer called PentixaFor can find multiple myeloma lesions more accurately than the standard FDG tracer during PET scans. Researchers will compare the two tracers in 45 patients who are either starting first-line treatment or have r…

This study tests whether a combination of three drugs (daratumumab, carfilzomib, and dexamethasone, known as DKd) can prevent or delay the development of full-blown multiple myeloma in people with high-risk smoldering multiple myeloma. Fourteen adults with this condition will rec…

This study tests whether adding acupuncture to standard pain care can lower the use of opioid painkillers in people with multiple myeloma, Hodgkin disease, or non-Hodgkin lymphoma who are about to receive high-dose chemotherapy. About 299 adults will be randomly assigned to get e…

This study tests whether siltuximab can lessen the severity of cytokine release syndrome (CRS) and nerve-related side effects (ICANS) that often occur after CAR-T cell therapy for blood cancers like lymphoma, multiple myeloma, and leukemia. About 30 participants will receive silt…

This study tests whether giving siltuximab before and after an autologous stem cell transplant can reduce symptoms like fatigue, pain, and nausea in patients aged 60 to 75 with multiple myeloma or AL amyloidosis. The drug blocks a protein called IL-6 that is linked to inflammatio…

This study tests a mobile app called THRIVE-M designed to help people with multiple myeloma improve their quality of life, reduce emotional distress, and lessen fatigue. About 120 adults with different stages of the disease will either use the app or receive usual care. The goal …

This study tests whether a 12-week personalized exercise program (a mix of aerobic and resistance training) can improve physical performance, quality of life, and reduce fall risk in people with multiple myeloma. About 45 patients will be split into high-risk (individual training…

This study tests whether analyzing the genes of a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to standard therapy are enrolled. The goal is to see if targe…

This study gathers information from 100 adults with breast, lung, gastrointestinal cancer, or multiple myeloma. Participants complete weekly online surveys about their symptoms and treatment experience for at least 12 weeks. The goal is to learn how symptoms change over time, not…

This study looks at how a genetic test called MMprofiler affects the treatment choices doctors make for people with active multiple myeloma. About 250 patients will take part, and doctors will fill out questionnaires before and after seeing the test results. The goal is to see if…

This study looks at whether a health technology program called All4Cure helps people with multiple myeloma become more involved in managing their own health. About 200 participants will fill out surveys over time to measure their confidence and ability to take action, as well as …

This study collects bone marrow and blood samples, along with medical history, from people with multiple myeloma, Waldenstrom macroglobulinemia, and related disorders. The samples are stored in a tissue bank for future research to understand what causes these cancers and how to i…

This study gathers information from 49 people with relapsed or hard-to-treat multiple myeloma and their doctors. The goal is to understand why some patients do not receive advanced cell therapies like stem cell transplants or CAR T-cell therapy. No new treatments are given; inste…

This study follows over 2,500 people with multiple myeloma to see how well approved treatments work in real-world settings, not just in controlled trials. It includes both newly diagnosed patients and those whose cancer has returned or stopped responding to therapy. The goal is t…

This study was designed to track how the immune system recovers after CAR-T cell therapy and whether a pneumonia vaccine (PCV-21) given six months later can work. It planned to enroll 50 adults with blood cancers or solid tumors. However, the study was withdrawn before any partic…

This study uses artificial intelligence to examine the shape and structure of individual myeloma cells from bone marrow samples. The goal is to predict genetic abnormalities that help doctors understand the severity of the disease. The approach aims to make testing faster, cheape…

This study collects tissue and blood samples from 2,400 people with early-onset breast, colon, kidney, liver, multiple myeloma, or prostate cancer. Researchers will analyze the samples to find genetic changes that may cause cancer at a young age, especially in racially and ethnic…

This study was planned to find the safest dose of the chemotherapy drug bendamustine for people with multiple myeloma that had not been cured by earlier treatments. It was a phase 1 trial, meaning it was the first step in testing the drug in humans. However, the study was withdra…

This study looks for a blood test that can predict infection risk in people with chronic lymphocytic leukemia or multiple myeloma. Researchers will analyze blood samples from 150 adults to find markers linked to infections. The goal is to help doctors prevent serious infections i…

This study monitors the safety of lenalidomide in over 900 adults newly diagnosed with multiple myeloma who cannot have a stem cell transplant. Researchers compare heart-related side effects between patients taking lenalidomide and those on other standard treatments. Participants…

This study was designed to see how the drug belantamab mafodotin behaves in people with multiple myeloma who also have liver problems. It would have compared patients with different levels of liver function to those with normal livers. However, the study was withdrawn before enro…

This study does not provide any new treatment. It follows up to 1,000 adults who previously received CAR T-cell gene therapy for blood cancers like lymphoma, leukemia, or multiple myeloma. The goal is to watch for long-term side effects, as required by regulators. Participants wi…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will store and study these samples over time to learn how cancer changes and why some treatments stop working. The goal is to improve future …

This study tests a new system that helps doctors better understand the needs of older adults with cancer. The system combines checks on aging, mental health, lifestyle, and social factors. About 35 patients aged 65 and older will try it during their first cancer visit. The goal i…

This study observes 75 adults with relapsed or refractory multiple myeloma who are already taking selinexor (Nexpovio®) combined with bortezomib and dexamethasone. Researchers track quality of life, side effects, and how well the treatment works in everyday medical practice. The …

This long-term study aims to understand why farmers and their families may have higher risks for certain cancers, like prostate cancer and lymphoma. Researchers are following about 90,000 pesticide applicators and their spouses in Iowa and North Carolina, collecting information o…